Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Carnaxide – page 6

674 clinical trials in Carnaxide, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Carnaxide at a glance
674
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

674 trials in Carnaxide

Open in trial search

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Safety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Siplizumab
  • Sponsor:Itb-Med LLC

Neoplasm

Recruiting

Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Terremoto Biosciences Inc.

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Etentamig
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Carnaxide

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on atherosclerotic cardiovascular disease and heart conditions, including trials evaluating new treatments for hypertrophic cardiomyopathy and pediatric heart failure.

  • Cardiovascular Disease Prevention
  • Heart Failure Management
  • Atrial Fibrillation Treatment

Research aims to reduce major cardiovascular events and improve patient outcomes through novel therapeutic approaches.

02 Nephrology Studies

Comprehensive research into kidney disorders, with a focus on IgA Nephropathy and innovative treatments for chronic kidney disease. Multiple trials are investigating new therapeutic options for patients with various forms of kidney dysfunction.

  • Kidney Transplantation
  • Lupus Nephritis
  • Glomerular Diseases

Studies aim to improve kidney function and reduce disease progression in patients with various renal conditions.

03 Metabolic Disorders

Advanced research targeting hypertriglyceridemia and related metabolic conditions. Studies focus on novel treatments for patients with severe metabolic disorders and associated cardiovascular risks.

  • Lipid Management
  • Secondary Hyperparathyroidism
  • Metabolic Disease Complications

Investigations concentrate on developing targeted therapies to address complex metabolic disorders and their complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.